ArticlePsychiatric services (Washington, D.C.)2019
The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder.
Article in Psychiatric services (Washington, D.C.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The Association Between Receiving Medications for Opioid Use Disorder and Human Immunodeficiency Virus Testing: Findings From the Rural Opioid Initiative.Journal of addiction medicine · 2026Article
- Telehealth Disparities in Outpatient Substance Use Disorder (SUD) Treatment among Medicaid Beneficiaries during COVID-19.Substance use & misuse · 2025Article
- Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020.Journal of substance use and addiction treatment · 2025Article
- Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.Journal of substance use and addiction treatment · 2024Review
- Association of Medicaid expansion with health insurance, unmet need for medical care and substance use disorder treatment among people who inject drugs in 13 US states.Addiction (Abingdon, England) · 2024Article
- The Impact of State Medicaid Eligibility and Benefits Policy on Neonatal Abstinence Syndrome Hospitalizations.Contemporary economic policy · 2024Article
- Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019.Drug and alcohol dependence · 2023Article
- Gaps and barriers in drug and alcohol treatment following implementation of the affordable care act.Drug and alcohol dependence reports · 2022Article
- Consumer Knowledge of Insurance Coverage of Alcohol Treatment Services in the United States: Changes Since 2015.Journal of studies on alcohol and drugs · 2022Article
- Effects of Medicaid expansion on alcohol and opioid treatment admissions in U.S. racial/ethnic groups.Drug and alcohol dependence · 2022Article
- Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.Journal of substance abuse treatment · 2022Article
- Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.Drug and alcohol dependence · 2021Article
- Medicaid Expansion and Low-Income Adults with Substance Use Disorders.The journal of behavioral health services & research · 2021Article
- Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.Substance abuse treatment, prevention, and policy · 2021Article
- Changes in Buprenorphine Treatment After Medicaid Expansion.Psychiatric services (Washington, D.C.) · 2021Article
- Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies.Health affairs (Project Hope) · 2021Article
- "It's Helped Me a Lot, Just Like to Stay Alive": a Qualitative Analysis of Outcomes of a Novel Hydromorphone Tablet Distribution Program in Vancouver, Canada.Journal of urban health : bulletin of the New York Academy of Medicine · 2021Article
- Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study.Drug and alcohol dependence · 2021Article
- Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.Psychiatric services (Washington, D.C.) · 2021Article
- Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study.Drug and alcohol dependence · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objectiveThe study examined whether the use of opioid agonist therapy (OAT) for treatment of opioid use disorder in specialty substance use treatment settings increased following Medicaid expansion.
methodsAdministrative data on 943,430 admissions from the Treatment Episodes Data Set-Admissions (2010-2016) were used to examine the association between Medicaid expansion and the use of OAT and to assess whether this association was mediated by increased proportion of admissions with Medicaid in expansion states.
resultsFrom 2010-2013 to 2014-2016, OAT use among patients with opioid use disorder increased in both expansion (39.1% and 50.2%, respectively) and nonexpansion (39.9% and 40.5%, respectively) states. The effect of Medicaid expansion on OAT use was mainly mediated through a larger proportion of admissions with Medicaid in expansion states.
conclusionsAs the nation grapples with the opioid epidemic, expanding Medicaid coverage has the potential to promote greater access to evidence-based treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.